M
Monica Lencioni
Researcher at University of Pisa
Publications - 50
Citations - 1326
Monica Lencioni is an academic researcher from University of Pisa. The author has contributed to research in topics: FOLFIRINOX & Irinotecan. The author has an hindex of 15, co-authored 48 publications receiving 1190 citations.
Papers
More filters
Journal ArticleDOI
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study
Armando Santoro,Lorenza Rimassa,Ivan Borbath,Bruno Daniele,Stefania Salvagni,Jean-Luc Van Laethem,Hans Van Vlierberghe,Jörg Trojan,Frank T. Kolligs,Alan Weiss,Steven A. Miles,Antonio Gasbarrini,Monica Lencioni,Luca Cicalese,Morris Sherman,Cesare Gridelli,Peter Buggisch,Guido Gerken,Roland M. Schmid,Corrado Boni,Nicola Personeni,Ziad Hassoun,Giovanni Abbadessa,Brian Schwartz,Reinhard von Roemeling,Maria Lamar,Yinpu Chen,Camillo Porta +27 more
TL;DR: Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumours.
Journal ArticleDOI
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
Emilio Bajetta,Irene Floriani,M. Di Bartolomeo,R. Labianca,Alfredo Falcone,F. Di Costanzo,Giuseppe Comella,Dino Amadori,Carmine Pinto,Chiara Carlomagno,Donato Nitti,Bruno Daniele,Enrico Mini,Davide Poli,Armando Santoro,Stefania Mosconi,Rossana Casaretti,Corrado Boni,Graziella Pinotti,P. Bidoli,Lorenza Landi,Gerardo Rosati,Alberto Ravaioli,Maurizio Cantore,F. Di Fabio,Enrico Aitini,Alberto Marchet,Eliana Rulli,M. Cropalato Di Tullio,F. Galli,Elena Biagioli,I. De Simone,S. Mangano,Maurizio Tonato,Emanuele Zucca,Maria Grazia Valsecchi,S. De Placido,Laura Catena,M. Schiavo,Ilaria Proserpio,Roberto Bordonaro,Stefano Cordio,G. Burrafato,Anna Maria Bochicchio,Michele Aieta,Nicola Fazio,Francesca Spada,Vito Amoroso,G. Marini,H. Soto Parra,G. Novello,Bruno Massidda,Maria Teresa Ionta,M. Comandé,R. Venezia,Alessandro Bertolini,E. Menatti,L. Zanlorenzi,A. Colombo,A. Iop,S. Bonura,E. Mazza,Maria Grazia Viganò,Antonio Ardizzoia,Stefania Dell'Oro,G. Lo Re,Davide Adriano Santeufemia,Angela Buonadonna,D. Luisi,Giovanni Ucci,G. Di Lucca,Andrea Bonetti,Francesca Bergamo,M. Alù,F. Vastola,Piero Marchetti,Domenico Corsi,Elena Massa,G. Di Pinto,M. Duro,C. Oliani,M. Franchini,A. Inzoli,Nicola Gebbia,Lazzaro Repetto,Selene Rota,L. Frontini,Antonello Quadri,S. De Grossi,Marina Cazzaniga,F. Villa,Paolo Foa,Daris Ferrari,C. Rabbi,Sandro Barni,Fausto Petrelli,Monica Giordano,G. Luchena,M. Pirovano,A. Nasisi,Vincenzo Catalano,Paolo Giordani,A. Zaniboni,Francesco Leone,S. Ferrario,Giordano D. Beretta,Ettore Tito Menichetti,Davide Conte,D. Mari,Rocco Giannicola,Chiara Pierantoni,A.G. Luporini,Davide Tassinari,M. Nicolini,Giovanni Luca Frassineti,Daniele Turci,F. Zumaglini,Stefano Tamberi,A. Piancastelli,Giorgio Cruciani,Gabriele Minuti,M. Orlandi,Andrea Mambrini,A. Ciarlo,D. Cavaciocchi,F. Del Monte,S. Ricci,M.I. Brunetti,Monica Lencioni,Michele Sisani,Pietro Sozzi,Cristina Granetto,Silvana Chiara,A.S. Galetto,A.S. Ribecco,Andrea Decensi,Libero Ciuffreda,Editta Baldini,Roberta Camisa,R. Todeschini,Lorenza Rimassa,C. Carnaghi,T. Pressiani,Ermanno Rondini,R. Gnoni,Silvia Gasperoni,Luigi Cavanna,M.A. Palladino,Rodolfo Mattioli,G. Laici,Francesca Pucci,Massimo Alessio,I. Bernardini,Gianluca Tomasello,G. Baldino,R. Rossetti,S. Giaquinta,F.L. Rijas Llimpe,Alba A. Brandes,M. Marzola,Vincenzo Montesarchio,A. Rea,G. Genua,Lucrezia Silvestro,M. Montano,M.G. Sarobba,Giovanni Sanna,G. Filippelli,G. Dima,E. Greco,Mario Roselli,Donato Natale,G. Condemi,G. Fumi,Salvatore Tafuto,P. Masullo,G. Tiberio,G. De Manzoni,G. Fiorentini,Roberto Mazzanti,A. De Stefano,Giacomo Cartenì,M. Otero +182 more
TL;DR: A more intensive regimen failed to show any benefit in disease-free and OS versus monotherapy, and a sequential treatment of FOLFIRI followed by docetaxel plus cisplatin improves disease- free survival in comparison with 5-FU/LV in patients with radically resected gastric cancer.
Journal ArticleDOI
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
Carmelo Bengala,Valentina Guarneri,Elisa Giovannetti,Monica Lencioni,E. Fontana,Valentina Mey,A Fontana,Ugo Boggi,M Del Chiaro,Romano Danesi,Sergio Ricci,Franco Mosca,M. Del Tacca,Pierfranco Conte +13 more
TL;DR: The maximum-tolerated dose (MTD) of fixed dose rate (FDR) of gemcitabine infusion with circulating haemopoietic progenitor support is defined and a significant relationship was found between the AUC of dFdU and CdA expression and activity (P<0.05).
Journal ArticleDOI
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Alfredo Falcone,Antonello Di Paolo,Gianluca Masi,Giacomo Allegrini,Romano Danesi,Monica Lencioni,Elisabetta Pfanner,Silvia Comis,Mario Del Tacca,Pierfranco Conte +9 more
TL;DR: The sequence of treatment with irinotecan and infusional 5-FU affects the tolerability of this combination, with an improved tolerability for irinOTecan followed by5-FU.
Journal ArticleDOI
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
Lorenza Rimassa,Giovanni Abbadessa,Nicola Personeni,Camillo Porta,Ivan Borbath,Bruno Daniele,Stefania Salvagni,Jean-Luc Van Laethem,Hans Van Vlierberghe,Jörg Trojan,Enrico N. De Toni,Alan Weiss,Steven A. Miles,Antonio Gasbarrini,Monica Lencioni,Maria Lamar,Yunxia Wang,Dale Shuster,Brian Schwartz,Armando Santoro +19 more
TL;DR: Tumor MET levels were higher in patients treated with sorafenib and circulating biomarkers such as MET and HGF may be prognostic in second-line HCC, and results need to be confirmed in larger randomized clinical trials.